Open AccessMonitoring plasma imatinib level to improve results of therapy of chronic myeloid leukosis
Author(s) -
М. И. Савельева,
А. V. Kryukov
Publication year - 2017
Publication title -
kliničeskaâ medicina
Language(s) - English
Resource type - Journals
eISSN - 2412-1339
pISSN - 0023-2149
DOI - 10.18821/0023-2149-2017-95-1-36-44
Subject(s) - medicine , imatinib , myeloid leukemia , adverse effect , chronic myeloid leukaemia , drug , oncology , disease , intensive care medicine , therapeutic drug monitoring , pharmacology
The achievement of early cytogenetic and molecular responses is the major objective of therapy and a main prerequisite for the favourable long-term outcome of the disease. The maintenance of dose intensity and management of adverse events are keys to successful treatment of chronic myeloid leukemia (CML) with imatinib. Therapeutic monitoring and testing the drug level in blood are the efficient tools for the treatment ofpatients with CML and can be usedfor analysis of treatment failure or suboptimal response to therapy, suspected noncompliance, drug interactions or unexpected adverse reactions.